Shimura, Masahiko Tokyo Medical University
Kitano, Shigehiko Tokyo Women’s Medical University
Muramatsu, Daisuke Tokyo Medical University
Fukushima, Harumi Tokyo Women’s Medical University
Takamura, Yoshihiro University of Fukui
Matsumoto, Makiko Nagasaki University
Kokado, Masahide Wakayama Medical University
Kogo, Jiro St. Marianna University School of Medicine
Sasaki, Mariko Tachikawa Hospital
Morizane, Yuki Okayama University
Kotake, Osamu Tokyo Medical University
Koto, Takashi Kyorin University
Sonoda, Shozo Kagoshima University
Hirano, Takao Shinshu University
Ishikawa, Hiroto Hyogo College of Medicine
Okamoto, Fumiki University of Tsukuba
木下, 貴正 Sapporo City General Hospital
Kimura, Kazuhiro Yamaguchi University
Sugimoto, Masahiko Mie University
Yamashiro, Kenji Japanese Red Cross Otsu Hospital
Suzuki, Yukihiko Hirosaki University
Hikichi, Taiichi Hikichi Eye Clinic
Washio, Noriaki Showa General Hospital
Sato, Tomohito National Defense Medical College
Ohkoshi, Kishiko St. Luke’s International Hospital
Tsujinaka, Hiroki Nara Medical University
Kusuhara, Sentaro Kobe University
Kondo, Mineo Mie University
Takagi, Hitoshi St. Marianna University School of Medicine
Murata, Toshinori Shinshu University
Sakamoto, Taiji Kagoshima University
To investigate real-world outcomes for best-corrected visual acuity (BCVA) after 2-year clinical intervention for treatment-naïve, centr-involving diabetic macular oedema (DME).
Retrospective analysis of longitudinal medical records obtained from 27 institutions specialising in retinal diseases in Japan. A total of 2049 eyes with treatment-naïve DME commencing intervention between 2010 and 2015 who were followed for 2 years were eligible. Interventions for DME included anti-vascular endothelial growth factor (VEGF) therapy, local corticosteroid therapy, macular photocoagulation and vitrectomy. Baseline and final BCVA (logMAR) were assessed. Eyes were classified by the treatment pattern, depending on whether anti-VEGF therapy was used, into an anti-VEGF monotherapy group (group A), a combination therapy group (group B) and a group without anti-VEGF therapy (group C).
The mean 2-year improvement of BCVA was −0.04±0.40 and final BCVA of >20/40 was obtained in 46.3% of eyes. Based on the treatment pattern, there were 427 eyes (20.9%) in group A, 807 eyes (39.4%) in group B and 815 eyes (39.8%) in group C. Mean improvement of BCVA was −0.09±0.39, –0.02±0.40 and −0.05±0.39, and the percentage of eyes with final BCVA of >20/40 was 49.4%, 38.9%, and 52.0%, respectively.
Following 2-year real-world management of treatment-naïve DME in Japan, BCVA improved by 2 letters. Eyes treated by anti-VEGF monotherapy showed a better visual prognosis than eyes receiving combination therapy. Despite treatment for DME being selected by specialists in consideration of medical and social factors, a satisfactory visual prognosis was not obtained, but final BCVA remained >20/40 in half of all eyes.
British Journal of Ophthalmology
BMJ Publishing Group
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
bjophthalmol_104_9_1209.pdf 380 KB